LOGO

Checklist: The Power Of Science

From cancer to COVID-19 monoclonal antibody therapy, Regeneron focuses on R&D and homegrown technologies to fight serious diseases.
Posted on Sep 28, 2021 | 12:30pm
Spotlight | Brought to you by Watch

Founded and led for over 30 years by physician-scientists, aims Regeneron Pharmaceuticals Inc. makes life-transforming medicines that help treat serious diseases. Patients suffering from a broad range of serious conditions—including retinal eye diseases, cancer, rheumatoid arthritis, asthma, atopic dermatitis, pain and infectious diseases—have benefitted from the Regeneron's cutting-edge research and inventions.

The pharma leader has also recently announced that the U.S. Department of Health and Human Services, along with the Department of Defense, will purchase 1.4 million additional doses of its REGEN-COV, to be delivered starting in September 2021, with delivery to be completed by January 31, 2022. A monoclonal antibody cocktail designed to block the infectivity of Sars-CoV-2, the virus that causes COVID-19, REGEN-COV comprises two virus-neutralizing antibodies that bind to the receptor-binding domain of the virus' spike protein, diminishing the virus' ability to mutate and escape treatment, and protecting against the spike variants currently circulating in the US, such as Delta, Gamma, Beta, and Mu.

Classified as an investigational medicine, REGEN-COV is authorized by the FDA under an EUA (emergency use authorization) to treat high-risk individuals who are infected with COVID-19 but not hospitalized, or in certain circumstances, to be used as a preventative. Regeneron's new agreement brings the U.S. government's total purchases of REGEN-COV to 3 million doses. Discover more at regeneron.com.

Photo Credit: Getty Images